Andere talen Hinova Pharmaceuticals Inc.

Aandelen

688302

CNE1000059F5

slotkoers Shanghai S.E. Andere beurzen 00:00:00 20-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
27,04 ^CNY	-0,37%		-4,32%	-48,07%

26/04	Hinova Pharmaceuticals Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
08/04	Chinese aandelen dalen in aanloop naar publicatie economische gegevens maart	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
China Stocks Fall Ahead of March Economic Data Release	08/04
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%	08/04
China Healthcare Stocks Rally on Hopes for Government Support	14/03
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets	23/02
Hinova Pharmaceuticals Gets US FDA's Nod to Conduct Phase II Clinical Trial on HP501 Tablets	07/12
Hinova Pharmaceuticals Gets Nod to Test Prostate Cancer Drug	03/11
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	27-10-23
Hinova Pharmaceuticals to Resubmit Application for Deuterated Enzalutamide Soft Capsules	23-10-23
Hinova Pharmaceuticals Inc.(XSSC:688302) added to S&P Global BMI Index	18-09-23
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	30-08-23
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	27-04-23
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange Composite Index	13-04-23
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange A Share Index	13-04-23
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27-02-23
Hinova Pharma Gets Regulatory Nod for Anti-Tumor Drug Trial	10-02-23
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment	06-02-23
Hinova Pharmaceuticals Gets FDA's Nod to Hold Trial on Anti-Cancer Drug; Shares Jump 5%	01-02-23
MagicRNA announced that it has received $2.900000 million in funding from Goldport Capital, Shenzhen Credit Guarantee Group Co., Ltd, Hinova Pharmaceuticals Inc., NLPE, Shenzhen Hongtao Fund Management Co., Ltd. and other investors.	30-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hinova Pharmaceuticals Inc.

Aandelen

688302

CNE1000059F5

Andere talen

Filters